Microsoft word - breast augmentation by the effect of phytoestrogen.doc

Breast Augmentation by The Effect of Phytoestrogen
The catholic University of Korea, Saint Mary's Hospital Orthopaedic Department, Seoul, Korea Jin Wha Chung, M.D.
The phytoestrogen has the positive effect in osteoporosis, cardiovascular diseases, facial flushing and other postmenopausal symptoms. And the purpose of this study was to evaluate the effect of phytoestrogen in increasing breast size clinically and histological. The result show meaningful augmentation of the breast in group taken phytoestrogen tablets ( ERDIC) and in mouse study, study group showed more lobules and more duct cells in lobules than control group histological. The results mean phytoestrogen has weak estrogenic effect on the lobular structures of the breast tissue and finally increasing their size without any significant side effect.
1. Introduction

Women's breasts increase during adolescence and pregnancy, and to a lesser extent the same phenomenon occurs during the menstrual period. All of these are concerned with female hormones. The breast increase resulting from hormones has been reported clinically among patients who take estrogen hormones, antidepressants and contraceptives. Furthermore, it is known that substances such as female hormones, prolactin and growth factors play a role in triggering these reactions, stimulating estrogen receptors distributed across lobules and modulating cell division and apoptosis. Breast-augmentation surgery has been performed on premonopausal women for the purpose of beauty enhancement, that is, to increase the size of the breasts. However, issues such as high cost, post-surgery infection attributed to the materials inserted within the breasts, tissue rejection, have effectively limited the use of such procedures. Additionally, in recent years the use of estrogen, a female hormone taken by menopausal women, has decreased due to the increasing occurrence of breast and uterine cancers resulting from long-term use of the hormone. Compared to estrogen, phytoestrogen originates in plants. Recently many foods and extracts containing this substance have been used for the treatment of menopausal symptoms, and it has been shown that phytoestrogen is effective in decreasing the frequencies of breast and uterine cancers, and in preventing osteoporosis and cardiovascular disease. Specifically, for Asian people such as Chinese, and for Japanese living in the United States, the frequency of breast cancer is low. Moreover, the occurrence of flushing--one of the menopausal symptoms--now stands at just 20%, dramatically lower than 80% of Western women. It is believed that one of the most significant factors is that phytoestrogen is contained in many foods common to Asian diets. Since the 1980s, research on phytoestrogen has been led by American and European governments, as well as by manufacturers of soy-based foods. Thereafter, many menopausal women have taken phytoestrogen as a natural alternative in light of their concerns about the side effects of the hormonal treatment previously used. The Food and Drug Administration (FDA) of the United States declared in 1999 that foods containing soy proteins in excess of 25 grams (such as soy, soybean milk, tofu, etc.) have low amounts of saturated fatty acid and cholesterol, and that they are effective for preventing cardiac diseases. Lamartiniere et al. (1998) claimed that an injection of genistein, a type of phytoestrogen, into a mouse less than 50 days old promoted the differentiation and maturation of mammary glands and thus contributed to reducing the occurrence of cancer
against a carcinogen. Wang et al. (1995) claimed that an injection of the isoflavone formonenelin
into the mouse whose ovary was removed led to the increase of prolactin in blood plasma and thus
the augmentation of lobules.
During our experiments in the induction of osteogenesis against osteoporosis, we speculated that if
for young women who are premenopausal, taking phytoestrogen promotes the differentiation and
development of mammary glands and thus augments the breasts, it could be an alternative against
breast-augmentation surgery--which despite its wide use has been rife with side effects--and
against other medicines. Therefore, we devised this experiment.
2. Methods

1. Phytoestrogen tablets
ERDICR (Glennrock BV, Netherlands) was used in this study. One tablet of this product weighs approximately one gram (0.996±0.023 gram) and is composed of substances extracted from hops,
buckwheat, fennel seed, rye, barley, etc. In order to analyse the ingredients of this product, it was
grounded with a mortar and crushed with a homogenizer filled with 1 liter of 100% methanol,
whereupon the effective substances within it were extracted. All these processes were repeated
three times and the supernatant was collected, concentrated and then redissolved in small amount
of methanol for a final concentration of 50%. Subsequently it was loaded on a column saturated
with hydrophobic interaction chromatography resin. Consequently we confirmed through
chromatography that this product contains a large amount of genistein and diadzein.
2. Subjects and Methods
1) Experiment with premenopausal women We had thirty premenopausal women ages 24 to 35 (mean age 27.3) take the ERDICR tablets for 6 months continuously. They took 10 tablets daily--five in the morning and five in the afternoon--30 minutes after each respective meal. Participants' weights and breast sizes were measured at the beginning prior to taking tablets, and again at three months and six months after taking them. The breast size was measured from [illegible] to the nipples in a standing posture, and the values of liver (SGOT/PT) and renal (BUN/Creatinine) function and cholesterol were compared through blood tests. 2) Animal experiment with mice Thirty female mice were divided into two groups: an experimental and a control group. They were 12 weeks old, 140-200 grams in weight, and of the Sprague-Dawley strain. For the control
group we fed an assorted feed without beans (Shin Chon Feed, Kimpo Kyunggido) and tap water,
while for the experimental group we added 10 ground-up ERDICR tablets per day to the same diet
used for the control group. We obtained lobules from the slaughtered mice after three months'
experiment. The lobules thus obtained were fixed by soaking in 10% formalin solution for 12
hours. Tissue slices 5 µm thick were obtained by common tissue-production procedures and
subjected to hematoxylin & eosin (H&P) staining [some words illegible]. We first examined the
nipple tissues under 40× magnification and, based on that, compared the number of lobules located
in hypodermic muscular coat. We also compared the number of cells that are constituent of lobules
under 100× magnification.

The mean weight of 30 women was increased from 53.7 kg at the beginning to 54.4 kg in six months, and mean breast size increased from 84.3 cm ( 33.19 inches) at the beginning to 87.9 cm (34.61 inches) in six months. In order to exclude the effect of breast augmentation by the increased weight of the participants, we compared results at intervals of three months: the

beginning, three months and six months. Although there was no significant difference in breast augmentation between the 1st 3 months-0.7371 p=0.3659) and next 3 months (-1.0665, p=0.1122), the difference between the 1st months and 6th month was significant (1.8036, p=0.0038). Statistically, we used the Bonferroni method for p value, with a negative estimate taken to indicate that breast size measured at a later time was greater than one measured in the former time (Table 1, 2). We checked the items listed on the blood test before and after the experiments, and no significant difference or abnormal condition was examined. Meanwhile, in terms of the histological tests obtained from the mouse experiment, under 40x magnification we could identify the increasing number of mammary glands at six months
compared to those at the beginning, and under 100x magnification we could see the increase of
cells constituent of mammary glands (Fig. 1, 2).
Table 1. Mean weight at each interval
Fig. 1. Cells of mouse breast tissue under 40x magnification
Fig. 2. Cells of mouse breast tissue under 100x magnification (A: beginning, B: 3 months)
Table 1

Minimum Maximum 53.7222222 7.2222058 47.5000000 69.5000000 53.3888889 7.0388118 47.0000000 69.0000000 54.3888889 7.4257003 48.0000000 70.5000000
Table 2

Effect time _time weight
Estimate Std Error DF t Value Pr>t Adjustment ADJ P 15 -1.64 0.1220 Bonferroni 0.3659 1 3 53.70 -1.8036 0.4562 15 - 3.95 0.0013 Bonferroni 0.0038 2 3 53.70 -1.0665 0.4670 15 - 2.25 0.0374 Bonferroni 0.1122 Cells of mouse breast tissue under 40x magnification (A: beginning, B: 3 months)

Cells of mouse breast tissue under 100x magnification (A: beginning, B: 3 months)
4. Discussion

Among the various substances that exist within plants, "phytochemical" refers to chemical substances that affect human health, and phytoestrogen is one such type. Although phytoestrogen typically does not have the same steroid structure as endogenous estrogen, it shows physiological characteristics similar to estrogen. Presumably this is attributable to its aromatic A chain of steroid. Phytoestrogen exists in all kinds of plants. As long as humans consume foods, they are inevitably exposed to phytoestrogen at all times. Coumestan, lignan and isoflavon are representative substances of phytoestrogen, and among these the most studied isoflavon is contained in soy, tofu, etc., with genistein and daidzoin represented. These are absorbed within the stomach and converted into final products such as cauol and o-desmethyl-angolensin paraethyphenol. Of these, cauol is most similar to estrogen and functions by competitively binding with estrogen receptors. Although the affinity of phytoestrogen is not more than about 1/100,000 compared to endogenous estrogen, its concentration in the body is 100 times higher than the endogenous estrogen and thus it provides the effect of estrogen. Meanwhile, phytoestrogen compounds serve as estrogen analogue in low concentrations and promote cell proliferation, but instead they provide anti-estrogenic effects in relatively high concentration. Additionally, these isoflavon compounds affect cell proliferation and apoptosis induction through various external stimulus factors such as mitogen and eyetokin, and this can be performed without binding with estrogen receptors. The hormonal alternative treatment can increase bone density by approximately 3.5% to 5% in pre-and postmenopausal osteoporosis patients. The results of several studies show that in particular ipriflavon--a synthetic substance of isoflavon in phytoestrogen--helps patients to whom hormonal alternative treatment cannot be administered. Moreover, it has been shown to be effective against febrile flushing and atrophic vaginitis resulting from postmenopausal estrogen deficiency, and has even demonstrated its effectiveness against osteoporosis and cardiovascular disease. Consequently, research has shown that it can potentially serve as an alternative to the heretofore common use of estrogen. Whereas all past research results were obtained through tests using menopausal women as subjects, the purpose of this experiment was to examine how taking this phytoestrogen benefits young women of the current day, particularly in terms of breast size. According to this experiment, taking phytoestrogen is associated with the breast enhancement of menopausal women, and its mechanism is presumably, as the results of mouse experiment show, the increase in the number of mammary glands and their constituent cells. Other than that, there were some subjective changes. For instance, women who took phytoestrogen reported that their breast increased, and that their skin and hair became more beautiful. Meanwhile, no claim was made regarding side effects resulting from phytoestrogen. However, according to what has been reported so far, those who have allergies to soy-based foods
may have indigestion or immune response after taking it. Therefore, we recommend that those
who have had allergies to peanuts or soy-based foods in the past be cautious in taking


1) Amsterdam, J.D., Garcia Espagna, F., Goodman, D. Hooper, M., and Hornig- 10) Hartman, B.W., Laml, T., Kirchengast, S., Rohan, M. : Breast enlargement Albrecht, A.E. and Huber J.C.: Hormonal duringchronic antidepressant therapy. Breast Augmentation: prognostic relevance J.Affect Disord, 46(2): 151-6, 1997 of insulin –like growth factor-I. Gynecol 2) Anderson, T.J., Battersby, S, King, R.J., Endocrinol, 12(2): 123-7, 1998 McPherson, K., and Going, J.J.: Oral 11) Jernstrom H. and Ollson H.: Breast siae in contraceptive use influences resting breast relation to endogenous hormone levels, body proliferartion. Hum Pathol, 20(12): 1139-44, constitution, and oral contraceptive use in healthy null gravid women aged 19-25 years. 3) Bolega, C., Poli, A., Cignarella, A., and Am J Epidemiol 145(7): 571-80, 1997 Paoletti, R. : Phytoestrgens: pharmacological 12) Lamartiniere C.A., Zhang, J.X. and and therapeutic perspectives. Curr Drug Contreneo, M.S.: Genistein study in rats: Targets, 4(1): 77-87, 2003 potential for breast cancer prevention and 4) Cassidy, A. : Potential risks and benefits of reproductive and developmental toxicity. Am phytoestrogen-rich diets. Int J Vitam Nutr J Clin Nutr, 68( 6 suppl.): 1400S-1405S, Res, 73(2):120-6: 2003 5) Coldham, N.G., and Sauer, M.J.: 13) Messina, M.J., Persky, V., Stechell, K.D. and Identification, quantitation and biological Barnes S.: Soy intake and cancer risk: a activity of phytoestrogens in a dietry review of the in vitro and in vivo data. Nutr supplement for breast enhancement. Food Cancer, 21(2): 113-31, 1994 Chem Toxical, 39(12),: 1211-24, 2001 14) Tsourounis, S.: Clincal effect of 6) Cos, P., De Bruyne, T., Apers, S., Vanden phytoestrogens. Clin Obstet Gynecol, 44(4): Berghe, D., Pieters, L. and Vlietinck, A.J.: 836-42, 2001 Phytoestrogens: recent developments. Planta 15) Wan, W., Tanaka, Y., Han , Z., and Higuchi, Med, 69(7): 589-99, 2003 C.M.: Proliferative respons of mammary 7) Ewies, A.a.: Phytoestrogens in the glandular tissue to formononetin. Nutr management of the menopause: up-to-date. Cancer, 23(2): 131-40, 1995 Obstet Gynecol Surv, 57(5), 306-13,2002 16) Ganry, O.: Phytoestrogen and breast cancer 8) Ganry, O.: Phytoestrogen and breast cancer prevention. Eyr J. Cancer Prev, 11(6) 519- prevention. Eyr J. Cancer Prev, 11(6) 519- 17) Garrte, S.D, Lee, H.A., Friar, P.M. and 9) Garrte, S.D, Lee, H.A., Friar, P.M. and Morgan, M.R.: Validation of a novel estrogen Morgan, M.R.: Validation of a novel estrogen receptotr-based microtiration plate assay for receptotr-based microtiration plate assay for the determination of phytoestrogen in soy the determination of phytoestrogen in soy basd foods, J.Agric Food Chem, 47(10): basd foods, J.Agric Food Chem, 47(10): 4106-11, 1999 4106-11, 1999 18) Wuttke, W., Jarry, H., Westphalen, S., Christoffel, V; and Seidlova-Wuttke, D., : Phytoestrogensfor hormone replacement therapy? J. Steroid Biochem Mol Biol, 83(1- 5): 133-47, 2002 Bron: Source: The Newest Medical Journal, Korea, 2003 11-12



REF. 9). Iproniazid, a drug registered for the treatment of tuberculosis, was found to elevate the mood of patients that received it,and subsequent studies in patients who were Is mood chemistry? depressed but did not have tuberculosisshowed its effect as an antidepressant9. Sim-ultaneously and independently, imipramine, Eero Castrén an experimental antihistamine with a tricyclicstructure, was found to have antidepressant

Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis James W.B. Bainbridge, Ph.D., F.R.C.Ophth., Alexander J. Smith, Ph.D., Susie S. Barker, Ph.D., Scott Robbie, M.R.C.Ophth., Robert Henderson, M.R.C.Ophth., Kamaljit Balaggan, M.R.C.Ophth., Ananth Viswanathan, M.D., F.R.C.Ophth., Graham E. Holder, Ph.D., Andrew Stockman, Ph.D., Nick Tyler, Ph.D., Simon Petersen-Jones, Ph.D.,